Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 27.
doi: 10.1111/jdv.20814. Online ahead of print.

Real-world outcomes of lebrikizumab treatment for upadacitinib-refractory atopic dermatitis

Teppei Hagino  1 , Marina Onda  1 , Hidehisa Saeki  2 , Eita Fujimoto  3 , Naoko Kanda  1
Affiliations

Real-world outcomes of lebrikizumab treatment for upadacitinib-refractory atopic dermatitis

Teppei Hagino et al. J Eur Acad Dermatol Venereol. .
No abstract available

Keywords: atopic dermatitis; biologic; interleukin‐13; lebrikizumab; upadacitinib.

PubMed Disclaimer

References

REFERENCES

    1. Nomura T, Sandilands A, Akiyama M, Liao H, Evans AT, Sakai K, et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol. 2007;119(2):434–440.
    1. Guttman‐Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once‐daily upadacitinib versus placebo in adolescents and adults with moderate‐to‐severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double‐blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168.
    1. Paller AS, Ladizinski B, Mendes‐Bastos P, Siegfried E, Soong W, Prajapati VH, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate‐to‐severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials. JAMA Dermatol. 2023;159(5):526–535.
    1. Gregoriou S, Koumprentziotis IA, Kleidona IA, Bakakis M, Hatzidimitriou E, Douvali T, et al. Successful achievement of demanding outcomes in upadacitinib‐treated atopic dermatitis patients: a real‐world, 96‐week single‐centre study. Dermatol Ther (Heidelb). 2025;15(1):227–235.
    1. Hagino T, Saeki H, Fujimoto E, Kanda N. A 96‐week real‐world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy‐naive versus ‐experienced patients. J Am Acad Dermatol. 2025;92(5):1049–1055.

LinkOut - more resources